Fludarabine: a phase II trial in patients with previously treated low-grade lymphoma.
The aim of the study was to investigate the therapeutic activity of Fludarabine in patients with low-grade non-Hodgkin's lymphoma (LG-NHL) no longer responding to standard treatment. In this Phase II study patients were treated with Fludarabine 25 mg/m2 intravenously daily for 5 days repeated at 28-day intervals. Twenty-two patients with LG-NHL, no longer responding to standard treatment, were entered in the study. Among twenty-one evaluable patients, seven had a complete and six a partial response. The median time to treatment failure and survival time are 4.6 months and >28.0 months, respectively. The most important toxicity was hemogram suppression, which was usually manageable but occasionally severe. Fludarabine is not only an active agent with definite therapeutic value in patients with treatment-resistant LG-NHL, but effective and well tolerated in patients no longer responding to standard treatment.
Falkson
C I
CI
Department of Medical Oncology, University of Pretoria, South Africa.
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D014740:Vidarabine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000970:Antineoplastic Agents; D014740:Vidarabine; C024352:fludarabine